

## **CLINICAL INSIGHTS**

BLUE CROSS Division of Blue Cross Laboratories

## **K-MET TABLETS**

*Issue IX, No.28, 2024* 

**Renal Protective Effect of Metformin in Type 2 Diabetes Patients** *Wang HH, et al. J Clin Endocrinol Metab.* 2024; 11:*dgae*477

- Preventing the onset and progression of diabetic kidney disease (DKD) is an important issue and the present study was conducted to assess the renoprotective effect of Metformin in patients with type 2 diabetes (T2DM).
- A total of 13,096 Metformin and 13,096 non-Metformin patients were included.
- The Metformin group had a significantly lower incidence of doubling of serum creatinine (incidence lowered by 29%), estimated glomerular filtration rate ≤15 mL/min/1.73 m<sup>2</sup> (incidence reduced by 39%) and end-stage kidney disease (incidence lowered by 45%) compared with the control group.
- When considering factors such as age, gender, comorbidities and medications in subgroup analyses, Metformin group experienced a slower deterioration in renal function across nearly all patient subgroups.

Renal function decline was less likely when taking Metformin.

\* \* \* \* \* \*